30 million for breast cancer trial So , if i heard from the fireside correctly today , they need 30 million to fund the next breast cancer trial . At theses levels that is approximately 30 million shares . They could exercise some of their options and help get the share price up with insider buying . They get it up enough past $3 , then maybe some warrants will get exercised . Between the options and the warrants , they wouldn't have to issue that many additional shares . At any rate - higher the share price - less dilution . Nice to see some questions being asked today from the attendees , not like the previous fireside . Still wish they would just sell things outright . $500 million would be a win for everyone at this stage , in my opinion .
sec.gov/Archives/edgar/data/1129928/000110465924085444/tm2420730d2_suppl.htm#B_014 Date of Grant Number of Stock Options Granted Exercise Price (C$) Expiry Date August 15, 2023 777,500 2.76 August 15, 2028 September 11, 2023 25,000 3.05 September 11, 2028 December 8, 2023 1,342,900 1.91 December 8, 2028 January 5, 2024 45,000 1.76 January 5, 2029 January 22, 2024 15,000 1.62 January 22, 2029 May 28, 2024 250,000 1.53 May 28, 2029
As of the date hereof, we have 7,667,050 Common Share purchase warrants (the “2023 Warrants”) issued and outstanding. Each 2023 Warrant entitles the holder to purchase one common share at an exercise price of US$2.81 until August 8, 2028.
As of the date hereof, we have 536,693 Common Share purchase warrants (the “2023 Compensation Warrants”) issued and outstanding. Each 2023 Compensation Warrant entitles the holder to purchase one common share at an exercise price of US$2.25 until August 8, 2028.